Active, not recruitingNCT04985643
A Study of Real Life Treatment for Multiple Myeloma (MM)
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Enrollment
- 357 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (24)
- Altai Regional Clinical Hospital, Barnaul, Altayskiy Kray, Russia
- Kaluga Regional Clinical Hospital, Kaluga, Central Federal District, Russia
- Smolensk Clinical Hospital of Russian Railways-Medicine, Smolensk, Central Federal District, Russia
- City Clinical Hospital No. 1 named after prof. S.I.Sergeev, Khabarovsk, Far Eastern Federal District, Russia
- Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Kirov Oblast, Russia
- GUZ "Lipetsk City Hospital No. 3" Free Falcon ", Lipetsk, Lipetsk Oblast, Russia
- National Research Center of Hematology of the Ministry of Health, Moscow, Moscow Oblast, Russia
- Herzen Moscow Scientific Research Oncological Institute, Moscow, Moscow Oblast, Russia
- Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky, Moscow, Moscow Oblast, Russia
- BaltikMed Clinic, Kaliningrad, Northwestern Federal District, Russia
- Vologda Regional Clinical Hospital, Vologda, Northwestern Federal District, Russia
- Novosibirsk State Medical University, Department of Therapy, Hematology and Transfusiology based on City Clinical Hospital No. 2, Novosibirsk, Novosibirsk Oblast, Russia
- Orenburgskaya Regional Clinical Hospital n.a. V.I. Voinova, Orenburg, Orenburgskaya District, Russia
- Republican hospital named after V.A.Baranov, Petrozavodsk, Republic of Karelia, Russia
- Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan', Republic Tatarstan, Russia
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04985643 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.
- RECRUITINGNANCT07359014Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaSecond Affiliated Hospital, School of Medicine, Zhejiang University